This Funding Opportunity Announcement (FOA) solicits pre-applications for projects that test new therapeutic uses for experimental drugs or biologics (Assets) across a broad range of human diseases in adult and pediatric populations. This innovative program allows investigators to propose new therapeutic uses for Assets from pharmaceutical company partners. Strong applications will include scientific evidence that modulation of an Assets target will have a positive impact on the disease/condition. Applicants whose X02 pre-applications are identified as being highly meritorious and relevant to NIH program priorities will be put in contact with the appropriate pharmaceutical company.
The NIEHS and partnering Institutes and Centers are establishing an infrastructure, the Human Health Exposure Analysis Resource (HHEAR) as a continuation of the Children's Health Exposure Analysis Resource (CHEAR). The goal of this consortium is to provide the research community access to laboratory and statistical analyses to add or expand the inclusion of environmental exposures in their research and to make that data publicly available as a means to improve our knowledge of the comprehensive effects of environmental exposures on human health throughout the life course. This FOA solicits the HHEAR Coordinating Center (U24) that will serve as the administrative hub and external access point for HHEAR, managing and tracking the flow of projects, materials, and analyses between HHEAR units and participating investigators. In addition, the coordinating center will support administrative functions such as convening HHEAR Steering and Executive Committee meetings, and organizing education, outreach, and publicity activities. The HHEAR project has multiple sub-opportunities, including grants for Targeted Exposure Analysis Laboratories, Untargeted Exposure Analysis Laboratories, Environmental Monitoring Laboratories, and a Data Repository, Analysis, and Science Center.
The purpose of this FOA is to identify and support a Data Integration and Resource Center (DIRC) for the Common Fund Acute to Chronic Pain Signatures (A2CPS) Program. The overall programmatic goal of the DIRC is to integrate the efforts of all funded components of the A2CPS and serve as a community-wide nexus for protocols, data, assay and data standards, and other resources generated by the A2CPS Program.
This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer Moonshot Initiative that is intended to accelerate cancer research. The purpose of this FOA is to establish centers of collaborating investigators with the goal of identifying and advancing research opportunities for translating immunotherapy concepts for children and adolescents with cancer toward clinical applications. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP): Recommendation (B) that calls for the establishment of a pediatric immunotherapy translational science network. The network was envisioned by the BRP as focusing on identifying new targets for immunotherapies, developing new pediatric immunotherapy treatment approaches (e.g., cancer vaccines, cellular therapy, combinations of immunotherapy agents, and others), and defining the biological mechanisms by which pediatric tumors evade the immune system. The Pediatric Immunotherapy Discovery and Development Network (PI-DDN) Centers will address and implement these BRP recommendations.
The AIMM Research Award is intended to support highly creative and conceptually innovative high-risk research with the potential to accelerate critical discoveries or major advancements that will significantly impact military health and medicine. AIMM initiative funding supports novel research concepts and other efforts that initiate or enhance potential game-changers that may not be supported by other funding mechanisms or core programs. Applications using synthetic or systems biology-based approaches or focused on autonomous healthcare are highly encouraged.
This RFA solicits applications from institutions to establish or enhance core facilities (laboratory, clinical, population-based, or computer-based) that will directly support cancer research programs to advance knowledge of the causes, prevention, and/or treatment of cancer or improve quality of life for patients with and survivors of cancer. A user group of Texas-based investigators must be identified, each of whom should have supported cancer research projects that will make use of the requested facility. This requirement is not intended to exclude early-career–stage investigators who have not yet secured peer-reviewed grant support. CPRIT is particularly interested in supporting core facilities that provide enabling services to cancer investigators from multiple Texas institutions. Limited Submission Applications are submitted through this Sharepoint site.
CPRIT High-Impact/High-Risk (HIHR) Research Awards seek to provide short-term funding to explore the feasibility of high-risk projects that, if successful, would contribute major new insights into the etiology, diagnosis, treatment, or prevention of cancers. Because HIHR Research Awards are designed to support new ideas, preliminary data are not required. Using this mechanism, CPRIT intends to support innovative, developmental projects that focus on exceptionally promising topics that are not yet sufficiently mature to compete successfully for more conventional funding. The HIHR Research Awards are expected to provide the foundation for individual or multiple investigator awards upon completion. Applicants must explain why more conventional sources of support are not available for the proposed research and how short-term funding will lead to strong applications for additional support. Limited Submission Applications are submitted through this Sharepoint site.
The ETRA is intended to bridge the gap between promising new discoveries achieved in the research laboratory and the commercial development of a therapeutic product, medical device, or diagnostic assay through activities up to and including preclinical proof-of-concept data that demonstrate applicability to the planned clinical scenario. The work funded under this RFA must be deemed sufficiently robust such that successful completion would result in a lead product that has compelling evidence of efficacy in qualified models, a favorable preliminary safety profile, and, for therapeutics, evidence of feasibility of scale-up and bulk synthesis. In other words, at the completion of the project it will be clear if the lead product under development has the attributes necessary to attract private investment to continue its development toward IND-enabling studies (IDE-enabling preclinical plan in the case of a medical device) and clinical evaluation. Limited Submission Applications are submitted through this Sharepoint site.
The multi-agency Ecology and Evolution of Infectious Diseases program supports research on the ecological, evolutionary, and social principles and processes that influence the transmission dynamics of infectious diseases. The central theme of submitted projects must be quantitative or computational understanding of pathogen transmission dynamics. The intent is discovery of principles of infectious disease transmission and testing mathematical or computational models that elucidate infectious disease systems. Projects should be broad, interdisciplinary efforts that go beyond the scope of typical studies. They should focus on the determinants and interactions of transmission among humans, non-human animals, and/or plants. This includes, for example, the spread of pathogens; the influence of environmental factors such as climate; the population dynamics and genetics of reservoir species or hosts; the feedback between ecological transmission and evolutionary dynamics; and the cultural, social, behavioral, and economic dimensions of pathogen transmission. Research may be on zoonotic, environmentally-borne, vector-borne, or enteric pathogens of either terrestrial or freshwater systems and organisms, including diseases of animals and plants, at any scale from specific pathogens to inclusive environmental systems. Proposals for research on disease systems of public health concern to developing countries are strongly encouraged, as are disease systems of concern in agricultural systems. Investigators are encouraged to develop the appropriate multidisciplinary team, including for example, modelers, ecologists, bioinformaticians, genomics researchers, social scientists, economists, epidemiologists, evolutionary biologists, entomologists, parasitologists, microbiologists, bacteriologists, virologists, pathologists or veterinarians, with the goal of integrating knowledge across disciplines to enhance our ability to predict and control infectious diseases.